Catégorie : Cannabis therapeutique

Renseignements destinés aux professionnels de la santé : Le cannabis (marijuana, marihuana) et les cannabinoïdes, Santé Canada, dernière version octobre 2018

Renseignements destinés aux professionnels de la santé : Le cannabis (marijuana, marihuana) et les cannabinoïdes (Version PDF - 2,690 Ko) https://www.canada.ca/fr/sante-canada/services/drogues-medicaments/cannabis/renseignements-medecins/renseignements-destines-professionnels-sante-cannabis-cannabinoides.html Santé Canada Auteur : Hanan Abramovici Ph.D. Co-auteurs : Sophie-Anne Lamour, Ph.D. et George Mammen, Ph.D. Nous republions cet excellent document de Santé Canada, et surtout, le résumé des indications reconnues, et envisagées, du cannabis thérapeutique.   Aperçu des énoncés récapitulatifs Les énoncés récapitulatifs suivants visent à résumer le contenu des sections 4.0 (Usages thérapeutiques possibles) et 7.0 (Effets indésirables) et leurs sous-sections respectives. Les énoncés récapitulatifs peuvent être également trouvés dans leurs sections et sous-sections respectives dans le corps même du document. Remarque: la plupart des études [...]

Lire la suite

Lifetime marijuana use in relation to insulin resistance in lean, overweight, and obese US adults, Gerard Ngueta & Ruth Ndjaboue, 2019

Lifetime marijuana use in relation to insulin resistance in lean, overweight, and obese US adults Gerard Ngueta, Ruth Ndjaboue Journal of Diabetes, 2019 https://doi.org/10.1111/1753-0407.12958 Abstract Background Obese individuals are more likely to show insulin resistance (IR). However, limited population studies on marijuana use with markers of IR have yielded mixed results. The aim of this study was to examine the association of marijuana use with IR in US adults with different body mass index (BMI) status. Methods Data from the 2009 to 2016 National Health and Nutrition Examination Survey (NHANES) were abstracted. Minimal lifetime marijuana use was estimated using the duration of regular exposure and frequency of use. [...]

Lire la suite

Flavonoid Derivative of Cannabis Demonstrates Therapeutic Potential in Preclinical Models of Metastatic Pancreatic Cancer, Michele Moreau et al., 2019

Flavonoid Derivative of Cannabis Demonstrates Therapeutic Potential in Preclinical Models of Metastatic Pancreatic Cancer Michele Moreau, Udoka Ibeh, Kaylie Decosmo Noella Bih, Sayeda Yasmin-Karim, Ngeh Toyang, Henry Lowe5 and Wilfred Ngwa Frontiers in Oncology, July 2019, Vol. 9, article 660. doi: 10.3389/fonc.2019.00660   Abstract Pancreatic cancer is particularly refractory to modern therapies, with a 5-year survival rate for patients at a dismal 8%. One of the significant barriers to effective treatment is the immunosuppressive pancreatic tumor microenvironment and development of resistance to treatment. New treatment options to increase both the survival and quality of life of patients are urgently needed. This study reports on a new [...]

Lire la suite

The Potential of Cannabidiol as a Treatment for Psychosis and Addiction : Who Benefits Most ? A Systematic Review, Albert Batalla et al., 2019

The Potential of Cannabidiol as a Treatment for Psychosis and Addiction : Who Benefits Most ? A Systematic Review Albert Batalla, Hella Janssen, Shiral S. Gangadin and Matthijs G. Bossong Journal of Clinical Medicine, 2019, 8, 1058 doi : 10.3390/jcm8071058 Abstract : The endogenous cannabinoid (eCB) system plays an important role in the pathophysiology of both psychotic disorders and substance use disorders (SUDs). The non-psychoactive cannabinoid compound, cannabidiol (CBD) is a highly promising tool in the treatment of both disorders. Here we review human clinical studies that investigated the ecacy of CBD treatment for schizophrenia, substance use disorders, and their comorbidity. In particular, we examined [...]

Lire la suite

Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence : A pilot randomized clinical trial, Jose M. Trigo et al., 2018

Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence : A pilot randomized clinical trial Jose M. Trigo, Alexandra Soliman, Lena C. Quilty, Benedikt Fischer, JuÈrgen Rehm, Peter Selby, Allan J. Barnes11¤a, Marilyn A. Huestis, Tony P. George, David L. Streiner, Gregory Staios, Bernard Le Foll PLoS ONE, 2018, 13, (1), e0190768. https://doi.org/10.1371/journal.pone.0190768   Abstract Background The current lack of pharmacological treatments for cannabis use disorder (CUD) warrants novel approaches and further investigation of promising pharmacotherapy. We previously showed that nabiximols (27 mg/ml Δ9-tetrahydrocannabinol (THC)/ 25 mg/ml cannabidiol (CBD), Sativex®) can decrease cannabis withdrawal symptoms. Here, we assessed in a pilot study the [...]

Lire la suite

CB 2 Cannabinoid Receptors as a Therapeutic Target – What does the Future Hold ?, Amey Dhopeshwarkar and Ken Mackie, 2014

CB 2 Cannabinoid Receptors as a Therapeutic Target - What does the Future Hold ? Amey Dhopeshwarkar and Ken Mackie Molecular Pharmacology, 2014, 86, 430–437 http://dx.doi.org/10.1124/mol.114.094649   ABSTRACT The past decades have seen an exponential rise in our understanding of the endocannabinoid system, comprising CB1 and CB2 cannabinoid receptors, endogenous cannabinoids (endocannabinoids), and the enzymes that synthesize and degrade endocannabinoids. The primary focus of this review is the CB2 receptor. CB2 receptors have been the subject of considerable attention, primarily due to their promising therapeutic potential for treating various pathologies while avoiding the adverse psychotropic effects that can accompany CB1 receptor–based therapies. With the appreciation that [...]

Lire la suite

Beta-caryophyllene is a dietary cannabinoid, Jürg Gertsch et al., 2008

Beta-caryophyllene is a dietary cannabinoid Jürg Gertsch, Marco Leonti, Stephan Raduner, Ildiko Racz, Jian-Zhong Chen, Xiang-Qun Xie, Karl-Heinz Altmann, Meliha Karsak and Andreas Zimmer PNAS (Proceedings of the National Academy of Sciences of the USA),  2008, 105, (26), 9099-9104. Doi : 10.1073/pnas.0803601105   Abstract The psychoactive cannabinoids from Cannabis sativa L. and the arachidonic acid-derived endocannabinoids are nonselective natural ligands for cannabinoid receptor type 1 (CB1) and CB2 receptors. Although the CB1 receptor is responsible for the psychomodulatory effects, activation of the CB2 receptor is a potential therapeutic strategy for the treatment of inflammation, pain, atherosclerosis, and osteoporosis. Here, we report that the widespread plant volatile [...]

Lire la suite

An Overview of Galenic Preparation Methods for Medicinal Cannabis, Luigi Romano and Arno Hazekamp, 2018

An Overview of Galenic Preparation Methods for Medicinal Cannabis Luigi Romano and Arno Hazekamp Current Bioactive Compounds, 2018, 14, DOI: 10.2174/1573407214666180612080412   Abstract : In recent years, the Cannabis plant (Cannabis sativa L.) has been rediscovered as a source of new medicines around the world. Despite the fact that a number of registered medicines have been developed on the basis of purified cannabis components, there is a rapid increasing acceptance and use of cannabis in its herbal form. Licensed producers of high quality cannabis plants now operate in various countries including The Netherlands, Canada, Israel, and Australia, and in many US states. The legal availability of [...]

Lire la suite

Cannabinoid CB1 and CB2 Receptor Signaling and Bias, Mikkel Soes Ibsen et al., 2017

Cannabinoid CB1 and CB2 Receptor Signaling and Bias Mikkel Soes Ibsen, Mark Connor, Michelle Glass Cannabis and Cannabinoid Research, 2017, Volume 2.1, 48-60 https://doi.org/10.1089/can.2016.0037   Abstract An agonist that acts through a single receptor can activate numerous signaling pathways. Recent studies have suggested that different ligands can differentially activate these pathways by stabilizing a limited range of receptor conformations, which in turn preferentially drive different downstream signaling cascades. This concept, termed “biased signaling” represents an exciting therapeutic opportunity to target specific pathways that elicit only desired effects, while avoiding undesired effects mediated by different signaling cascades. The cannabinoid receptors CB1 and CB2 each activate multiple pathways, [...]

Lire la suite

The International Congress on Clinical Trials in Cannabis, 24-25 October 2019, London UK

Welcome letter  |  Program  |  Registration  |  Abstract Submission Abstracts topics Phytocannabinoid study – strains, chemovars, entourage and molecules. Pharamacokinetics and pharmacodynamics of cannabinoids Prediction of response to cannabinoid treatment Clinical trials targeting Pain, GI Disorders, Palliative Care, Psychiatry and Neurological disorders New designs for cannabis clinical trials (including pragmatic trials and n=1) Clinical Registries Observational / Epidemiological studies: findings, interpretations, plans Phase 2/3/4 study findings and designs (including special populations) Meta- and composite- analyses: findings and methodology Regulatory, licensing, and development programme issues and plans Cannabinoid trial best conduct including GCP and site training Assessing safety of cannabinoid medications Innovative [...]

Lire la suite